Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Other comprehensive income/(loss)

Other comprehensive income/(loss) at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's other comprehensive income/(loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's other comprehensive income/(loss)?
Bicara Therapeutics (BCAX) reported other comprehensive income/(loss) of -$486K in Q1 2026.
What does other comprehensive income/(loss) mean?
The total of all non-owner changes in equity that are excluded from net income, adjusted for applicable income taxes. This figure represents items such as unrealized gains or losses on securities and foreign currency translation adjustments. It serves as a broader measure of financial performance beyond traditional accounting profit.